CTGF Human, HEK

Connective Tissue Growth Factor (CTGF) is part of the CCN protein family, which includes Cyr61, CTGF, Nov, WISP-1, WISP-2, and WISP-3. These proteins are secreted and interact with the extracellular matrix (ECM) and cell membranes. CCN proteins, classified as matricellular proteins, regulate various cellular processes like growth, specialization, survival, adhesion, and movement. They are present in tissues derived from all three embryonic germ layers and contribute to the development of organs like the kidneys, nervous system, muscles, bone marrow, cartilage, and bones. In adults, they are involved in wound repair, bone fracture healing, and diseases such as fibrosis, vascular conditions, and tumor formation. The full-length versions of these proteins can inhibit cell growth, while shorter versions may promote growth and act as oncogenes. The complete protein structure consists of four modules. Module I shares similarities with Insulin-like Growth Factor Binding Proteins (IGFBPs). Module II contains a region resembling the Von Willebrand Factor Type C repeat (VWC). Module III includes a region similar to Thrombospondin type 1 repeat (TSP1), involved in binding specific molecules and cell adhesion. Module IV, also known as CT, is essential for many functions of CCN proteins and resembles regions in other proteins like Von Willebrand's factor and mucins. It also has parts that resemble heparin-binding sites. Breakdown of the full-length CCN proteins, as observed with CCN2 and CCN3, may lead to smaller peptides with strong binding affinity for molecules that the full-length proteins bind weakly. While shortened CCN2 versions were biologically active, no specific activity has been found for shortened CCN3 versions. The process of creating these shortened proteins is unclear, but it's noteworthy that both CCN2 and CCN3 are cut at the same points. Increased CCN2 has been detected in various human diseases like invasive mammary ductal carcinomas and tumors. Studies show a link between CCN2 expression and the severity of chondrosarcomas. CCN2's role in brain tumor blood vessel formation is supported by its presence in both tumor cells and blood vessel cells. In astrocytomas, CCN2 is higher in aggressive tumors and significantly affects cell growth. Reducing CCN2 levels halts growth, while increasing it doubles the number of cells in a specific growth phase. Analysis reveals around 50 genes potentially responsible for CCN2's growth-promoting effects. Lastly, CCN2 was found in a greater number of immune cells in patients with acute lymphoblastic leukemia.

CTGF Human Recombinant, produced in HEK293 cells, is a 36kDa protein comprising 329 amino acids (residues 27-349), including a C-terminal 6xHis tag.

A clear, colorless liquid after filtration.

CTGF, after filtration (0.2µm), is provided in a solution of 0.1M Citrate buffer with a pH of 4.7 and 20% glycerol by weight.

For optimal storage, keep at 4°C if the entire vial will be used within 2-4 weeks. For longer periods, store frozen at -20°C. Adding a carrier protein (0.1% HSA or BSA) is recommended for extended storage. Avoid repeated freezing and thawing cycles.

SDS-PAGE analysis indicates a purity greater than 90.0%.

CCN2, NOV2, HCS24, IGFBP8, MGC102839, CTGF.

HEK293 cells.

QNCSGPCRCP DEPAPRCPAG VSLVLDGCGC CRVCAKQLGE LCTERDPCDP HKGLFCHFGS PANRKIGVCT AKDGAPCIFG GTVYRSGESF QSSCKYQCTC LDGAVGCMPL CSMDVRLPSP DCPFPRRVKL PGKCCEEWVC DEPKDQTVVG PALAAYRLED TFGPDPTMIR ANCLVQTTEW SACSKTCGMG ISTRVTNDNA SCRLEKQSRL CMVRPCEADL EENIKKGKKC IRTPKISKPI KFELSGCTSM KTYRAKFCGV CTDGRCCTPH RTTTLPVEFK CPDGEVMKKN MMFIKTCACH YNCPGDNDIF ESLYYRKMYG DMA HHHHHH.